Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Lillian L. Siu(The University of Texas MD Anderson Cancer Center), Azeez Farooki(Ontario Institute for Cancer Research), Afshin Dowlati(Case Western Reserve University), Janet Dancey(Ontario Institute for Cancer Research), Joanna M. Brell(Ontario Institute for Cancer Research), John P. Perentesis(Cincinnati Children's Hospital Medical Center), L. Austin Doyle(Ontario Institute for Cancer Research)
Cited by 231
Related Papers
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer
|JAMA Oncology|2016|721
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases
|JAMA Oncology|2022|557
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459